Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment.
Griseofulvin, an antibiotic used to treat dermatophystosis, was tested for carcinogenicity in mice, rats and hamsters. Three groups of mice and rats were given the drug in powdered diet in alternating 5-week periods for life, at dose levels of 3.0%, 1.5% and 0.3% (mice) and 2.0%, 1.0% and 0.2% (rats). A group of mice and 3 groups of hamsters received continuous daily treatment for life with griseofulvin at 3.0%, 1.5%, 0.3% and 0.1% dose levels respectively. A significant incidence of hepatic tumours was observed at the 2 higher treatment levels in mice. Also, statistically significant rates (P less than or equal to 0.001 and/or P less than or equal to 0.020) of thyroid tumours, indicating a dose-response, were recorded in male rats at the 2.0%, 1.0%, and 0.2% dose levels, and in females at the 2.0% and 1.0% dose levels. Hamsters did not develop neoplasms in response to treatment at any level.
D000236:Adenoma / Q000139:chemically induced* / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D005260:Female; D006118:Griseofulvin / Q000633:toxicity*; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced*; D008297:Male; D008647:Mesocricetus; D051379:Mice; D009374:Neoplasms, Experimental / Q000139:chemically induced; D051381:Rats; D013964:Thyroid Neoplasms / Q000139:chemically induced* / Q000473:pathology
D006118:Griseofulvin